Przedsiębiorstwo Farmaceutyczne Lek-Amsp. z o.o.
Manufacture of pharmaceutical preparations
Overview
Przedsiębiorstwo Farmaceutyczne Lek-Am manufactures generic medicines that meet EU quality requirements, and its production facility has an in-house laboratory. The company employs more than 500 people and works with clinical centers and scientific institutes on the registration of new medicines.
Financials
Revenue history (in m)
From the notes
| Profit allocation | Dividend and reserves | |
| Loans and borrowings | $9,417,378 | |
| Revenue structure | Sprzedaż produktów krajowa | |
| Contingent liabilities | $85,886,489 | |
| Receivables write-downs | $103,756 | |
| Management board pay | $2,142,245 |
Filing timeliness
Financial statements were filed on time, on average 36 days early. All were audited by a statutory auditor.
- 202502/07/2026
- 202408/07/2025
- 202305/07/2024
- 202212/07/2023
- 202107/07/2022
- 202022/04/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Trademarks
Przedsiębiorstwo Farmaceutyczne Lek-Am holds 124 active trademarks registered with the Polish Patent Office. 8 applications are pending. 245 marks have expired or were not registered. The first mark was filed in 2000.
| Mark | Protected until | |
|---|---|---|
| LEK-AM SR(word) | Nov 21, 2035 | |
| VORTIOLEK(word) | Aug 21, 2035 | |
| OLZAK(word) | Apr 9, 2035 | |
| FEXOMED(word) | Apr 3, 2035 | |
| Olzalek(word) | Apr 1, 2035 |
Authorized Representatives
Manner of representation
For submitting declarations of will in property and non-property matters and signing on behalf of the company, each member of the management board is authorised to act independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Andrzej Szczepan Wyrzykowskiage 75 | 16,700 | $911,237.17 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2000-10-11.
04 1240 1066 1111 0011 6770 6929- 09 1240 1066 1111 0011 6800 1331
- 82 1240 1066 1111 0011 6770 6495
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Land (incl. perpetual usufruct) | $8.2M$8,231,292 |
Buildings and premises | $6.9M$6,921,042 |
Secured liabilities
| Type | Creditor | |
|---|---|---|
Mortgage | ||
Mortgage | ||
Pledge |
Public aid
14 public aid cases recorded, with a total value of $11,356,626.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 30, 2026 | Aid for research and development projects: industrial research | $2.3M$2,291,951 | Prezes Agencji Badań Medycznych | |
| Jun 30, 2026 | Aid for research and development projects: fundamental research | $763.7K$763,671 | Prezes Agencji Badań Medycznych | |
| Jun 11, 2026 | Aid for research and development projects: experimental development | $2.5M$2,463,707 | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-04-01 | Development and comprehensive therapeutic evaluation of a complex medicinal product for breakthrough combination therapy to treat type II diabetes with coexisting obesity | $4.1M$4,062,763 | European Funds for a Modern Economy | |
| 2026-04-01 | AAC – multifunctional, multilayer medical dressing that accelerates wound healing and has broad antimicrobial activity | $2.6M$2,642,455 | European Funds for a Modern Economy |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $160,174,284.28 | anpharm.pl | ||
| Biofarmsp. z o.o. | $143,422,260.45 | biofarm.pl | ||
| Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - LekS.A. | $119,621,017.71 | hasco-lek.pl | ||
| Sciencepharmasp. z o.o. | $111,783,976.52 | sciencepharma.com | ||
| Delpharm PoznańS.A. | $110,900,246.81 | delpharm.com | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| ICN Polfa RzeszówS.A. | $85,044,250.03 | icnpolfa.pl | ||
| Synoptis Pharmasp. z o.o. | $79,311,000.88 | synoptispharma.pl | ||
| PolfarmexS.A. | $73,543,379.32 | polfarmex.pl | ||
| BiotonS.A. | $71,777,247.61 | bioton.com |
Change history
| Date | Event | |
|---|---|---|
| 2019-01-24 | Share capital increase (3,155,200.00 PLN → 3,373,400.00 PLN) | |
| 2016-06-27 | Share capital increase (3,150,200.00 PLN → 3,155,200.00 PLN) | |
| 2014-06-27 | Share capital increase (3,100,200.00 PLN → 3,150,200.00 PLN) | |
| 2011-09-28 | Share capital increase (100,200.00 PLN → 3,100,200.00 PLN) | |
| 2004-02-13 | Share capital increase (6,000.00 PLN → 100,200.00 PLN) |
FAQ
Last updated: 2026-07-15